Patrick F. Williams Appointed Chief Financial Officer of Staar Surgical

Source: Staar Surgical

Staar Surgical announced that Patrick F. Williams has joined the company as Chief Financial Officer, effective today. Mr. Williams is reporting to Caren Mason, President and Chief Executive Officer. His appointment is part of a planned transition following Deborah Andrews’ previously announced retirement. Ms. Andrews will continue in an advisory role to ensure a smooth transition of duties to Mr. Williams.

“Staar is pleased to have a financial leader of Patrick’s caliber join the team at a time of such significant global opportunity for our EVO family of lenses,” Caren Mason, President and CEO of Staar Surgical, said in a company news release. “Patrick has an impressive record of success in executive leadership roles in medical device. His financial and operational experience in leading consumer-facing and marketing focused medical device companies makes him well suited to join Staar. He has demonstrated a track record of success in significantly growing revenue and shareholder value.”

Mr. Williams joins Staar with over 20 years of financial and operational management experience with public companies. Mr. Williams was most recently at Sientra, where he initially served as the Chief Financial Officer before transitioning to the General Manager of the miraDry business unit. Prior to Sientra, Mr. Williams was Chief Financial Officer of ZELTIQ Aesthetics, Inc., a publicly-traded medical device company that was acquired in 2017. Mr. Williams has also served as Vice President at NuVasive, Inc., a San Diego-based medical device company, in strategy, finance and investor relations roles.

“I am incredibly excited to join Staar. The company has a unique opportunity to accelerate an already impressive growth trajectory and become the refractive procedure of choice for ophthalmic surgeons and patients around the world,” Mr. Williams said in the news release. “I look forward to working with Caren, the Staar team and applying my experience and deep understanding in building growth medical device companies to accomplish this goal.”



Related Content